Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCARDIOVASCULAR PHARMACOLOGY

Electrophysiological Characterization of the Prokinetic Agents Cisapride and Mosapride in Vivo and in Vitro: Implications for Proarrhythmic Potential?

Leif Carlsson, Gregory J Amos, Birgit Andersson, Lissen Drews, Göran Duker and Gunilla Wadstedt
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 220-227;
Leif Carlsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory J Amos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Andersson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lissen Drews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Göran Duker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunilla Wadstedt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In the present study the electrophysiological characteristics and the proarrhythmic potential of cisapride and a structurally related drug, mosapride, were compared. In the anesthetized guinea pig, cisapride andd-sotalol (0.01–10 μmol/kg i.v.,n = 6) dose-dependently prolonged the duration of the monophasic action potential recorded from the left ventricle. The maximal lengthening was 18 ± 3.2% at 1.0 μmol/kg (mean ± S.E.M., P < .01 vs. base line) and 19 ± 2.5% at 10 μmol/kg (P < .001) for cisapride andd-sotalol, respectively. In contrast, mosapride did not increase this variable. In a rabbit model of the acquired long QT syndrome, infusion of cisapride (0.3 μmol/kg/min for 10 min maximum,n = 6), but not mosapride or vehicle, was associated with a significant lengthening of the QTU interval (43 ± 3.8 ms, P < .01). Furthermore, torsades de pointes appeared in two of the six rabbits given cisapride. In isolated rabbit Purkinje fibers (PF), cisapride increased the action potential duration (48 ± 5.6% at 0.1 μmol/l, P < .01 vs. control,n = 4). Mosapride did not significantly influence the action potential duration (3 ± 2.0% increase at 1.0 μmol/l, n = 6). However, after mosapride was washed out, the addition of cisapride (0.1 μmol/l) caused a 46 ± 3.2% lengthening of the action potential duration (P < .01vs. 1.0 μmol/l mosapride). Early afterdepolarizations and triggered activity appeared in four of eight cisapride-superfused PF stimulated at a very low frequency (0.1 Hz). In isolated rabbit cardiomyocytes, cisapride concentration-dependently blocked (IC50 = 9 nmol/l) the rapid component of the delayed rectifying K+ current (IKr). Mosapride was approximately 1000-fold less potent in blocking IKr(IC50 = 4 μmol/l). It is concluded that the electrophysiological characteristics of cisapride may explain the recently reported propensity to prolong the QT interval and to induce torsades de pointes in susceptible patients, although a structurally related benzamide, mosapride, did not appear to have electrophysiological features of relevance for induction of torsades de pointes in common with cisapride.

Footnotes

  • Send reprint requests to: Dr. Leif Carlsson, Astra Hässle AB, Preclinical Research & Development, Cardiovascular Pharmacology, S-431 83 Mölndal, Sweden.

  • Abbreviations:
    EADs
    early afterdepolarizations
    Ikr
    rapidly activating delayed rectifier K+current
    MAP
    monophasic action potential
    MAPD75
    monophasic action potential duration at the 75% repolarization level
    ECG
    electrocardiogram
    HEPES
    N-2-hydroxyethylpiperazine-N′-ethanesulfonic acid
    • Received December 5, 1996.
    • Accepted March 21, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Electrophysiological Characterization of the Prokinetic Agents Cisapride and Mosapride in Vivo and in Vitro: Implications for Proarrhythmic Potential?
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCARDIOVASCULAR PHARMACOLOGY

Electrophysiological Characterization of the Prokinetic Agents Cisapride and Mosapride in Vivo and in Vitro: Implications for Proarrhythmic Potential?

Leif Carlsson, Gregory J Amos, Birgit Andersson, Lissen Drews, Göran Duker and Gunilla Wadstedt
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 220-227;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCARDIOVASCULAR PHARMACOLOGY

Electrophysiological Characterization of the Prokinetic Agents Cisapride and Mosapride in Vivo and in Vitro: Implications for Proarrhythmic Potential?

Leif Carlsson, Gregory J Amos, Birgit Andersson, Lissen Drews, Göran Duker and Gunilla Wadstedt
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 220-227;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preconditioning of Rat Heart with Monophosphoryl Lipid A: A Role for Nitric Oxide
  • TAS-301, an Inhibitor of Smooth Muscle Cell Migration and Proliferation, Inhibits Intimal Thickening after Balloon Injury to Rat Carotid Arteries
  • Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
Show more CARDIOVASCULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics